Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
https://doi.org/10.20996/1819-6446-2016-12-5-590-594
Abstract
Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has been shown in a retrospective analysis of patients from the RE-LY study. The incidence of stroke and systemic embolism within 30 days after cardioversion was low and did not differ significantly in all groups. Thus, the results of the RE-LY study allow performing the planned and emergency cardioversion in patients receiving dabigatran. These results were later confirmed in other retrospective studies and meta-analyzes that are presented in this article. The X-VERT study and sub-analysis of the ARISTOTLE study showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical cardioversion in patients with non-valvular AF. Long-term preparation courses for the cardioversion were used in the majority of patients in all published papers. By the present time a specially designed study directly aimed at assessing the NOAC effectiveness, in particular, dabigatran, in preparing and performing electrical cardioversion was not carried out in patients with AF. Some questions about the safety and efficacy of dabigatran during short preparation courses before electrical cardioversion remain.
About the Authors
N. A. Novikova
I.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 Russia
Russian Federation
Russian Federation
MD, PhD, Professor of Chair of Emergency and Preventive Cardiology, I.M. Sechenov First Moscow State Medical University
A. N. Volovchenko
I.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 Russia
Russian Federation
Russian Federation
MD, Physician of Intensive Care Unit №1, University Clinical Hospital №1, I.M. Sechenov First Moscow State Medical University
References
1. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. doi:10.1056/NEJMoa021375.
2. Roy D, Talajic M, Nattel S, et al. for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77.doi: 10.1056/NEJMoa0708789.
3. Van Gelder I, HagensV, BoskerHm, al. Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-50. doi: 10.1056/NEJMoa021375.
4. Arias MA, Casares-Medrano J, Pacho´n M, Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev EspCardiol 2012;65:489. doi:10.1016/j.recesp.2011.12.010.
5. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31: 967-75. doi: 10.1093/eurheartj/ehn599.
6. Klein A, Grimm R, Murray D, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20. doi: 10.1056/NEJM200105103441901.
7. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi: 10.1093/eurheartj/ehu367.
8. Nagarakanti R, Ezekowitz M, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123: 131-6. doi: 10.1161/CIRCULATIONAHA.110.977546.
9. Kalejs O, Sakne S, Litunenko O, et al. Safety and efficacy of Dabigatran versus Warfarin in patients with persistent and long-acting atrial fibrillation undergoing electrical cardioversion. J Am Coll Cardiol. 2014;63(12_S):A328. doi:10.1016/S0735-1097(14)60328-4.
10. Kalejs O, Sakne S, Litunenko O, et al. Two dosages Dabigatran versus Warfarin in patients with high risk of stroke and embolism undergoing electrical cardioversion with persistent and long-acting atrial fibrillation. Am Coll Cardiol. 2015;65(10_S):A353. doi:10.1016/S0735-1097(15)60353-9.
11. Johansson AK, Juhlin T, Engdahl J, et al. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? Europace. 2015;17(10):1514-7. doi: 10.1093/europace/euv123.
12. Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol. 2014;113(8):1362- 3. doi: 10.1016/j.amjcard.2013.12.044.
13. Caldeira D, Costa J, Ferreira JJ, et al. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol. 2015;104(7):582-90. doi: 10.1007/s00392-015-0821-8.
14. Law EH, Gordon W. Target-specific oral anticoagulants in patients undergoing cardioversion. Am J Health Syst Pharm. 2014;71(14):1171-6. doi: 10.2146/ajhp130548.
15. Coleman C, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015;38(6):731- 7. doi: 10.1111/pace.12618.
16. Pallisgaard JL, Lindhardt TB, Hansen ML, et al. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. PLoS One. 2015;10(10):e0141377. doi: 10.1371/journal.pone.0141377.
Review
For citations:
Novikova N.A., Volovchenko A.N. Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2016;12(5):590-594. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-5-590-594
Views:
853
.jpg)
Email this article 